B+
Bull case
30%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-06-12 · RankAlpha Sentiment Codex
EDIT
Editas MedicineBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is that Editas has sharpened into a single lead in vivo program, reiterated a mid-2026 IND/CTA path, still targets first-in-human initiation later in 2026, and had previously guided cash runway into the third quarter of 2027 before the late-May financing, which should extend flexibility further [#SEC-8K-2026-03-09] [#SEC-8K-2026-05-05] [#8-K-2026-05-26].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +0.7.
What can break
Clinical and regulatory execution risk remains high as the company transitions EDIT-401 from preclinical work into first-in-human testing.
Momentum
75
Value
41
Sentiment
69
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.80 · Bull $4.50 · Bear $1.40Analysis 2026-06-12; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-12 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $4.88
Why
Momentum75 · Δ7d -2.3
Value41 · Δ7d 0.0
Sentiment69 · Δ7d +0.7
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +0.7.
Contradictions & invalidation
- • Clinical and regulatory execution risk remains high as the company transitions EDIT-401 from preclinical work into first-in-human testing.
- • Editas remains pre-commercial with limited revenue visibility and ongoing cash burn, so additional capital needs cannot be ruled out even after the raise.
- • The bear case is that EDIT-401 is now doing most of the strategic heavy lifting, so any IND delay, clinical-start slippage, weak human translation, or safety issue could leave the stock with little support beyond cash value, while the May equity-plus-warrant financing reinforces dilution risk.
Catalyst clock
2026-06-30
EDIT-401 IND/CTA timing is the clearest mid-2026 proof point
Lead driver: Sentiment · See AI snapshot
Momentum
75
9% active weight
Current posture
7d trendSoftening
Δ7d
-2.3
Δ21d
-7.0
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
69
62% active weight
Current posture
7d trendSoftening
Δ7d
+0.7
Δ21d
+13.3
Why this grade
Composite grade B. Momentum 74.6 / Value 41.2 / Sentiment 68.9
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-12. Scenario method
Most likely
B
Base case
40%
Probability
Target price
$2.80
Analysis reference price unavailable
Analysis 2026-06-12 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-06-12 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$436.17M
Beta
2.15
Shares Out
153.58M
P/E (TTM) · Derived
-1.6
P/S (TTM)
4.19
P/FCF (TTM) · Derived
-2.35
Rev YoY
+232.3%
EPS YoY
-75.8%
Gross Margin
+94.8%
Op Margin
-177.6%
Net Debt
-$69.94M
Current Ratio
3.19
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data